<DOC>
	<DOCNO>NCT01357213</DOCNO>
	<brief_summary>This phase I , single-center , placebo-controlled , double-blinded , dose escalation study anti-botulinum toxin monoclonal antibody healthy adult volunteer . Volunteers hospitalize Johns Hopkins Phase 1 unit infusion 24-hour blood draw . Three escalate dose cohort combination three anti-botulinum monoclonal antibody evaluate . Each cohort consist eight volunteer receive single intravenous infusion active drug placebo . Placebo normal saline . Volunteers follow safety 120 day infusion depend dose cohort .</brief_summary>
	<brief_title>Phase 1 PK Study XOMA 3AB</brief_title>
	<detailed_description>This phase I , single-center , placebo-controlled , double-blinded , dose escalation study anti-botulinum toxin monoclonal antibody healthy adult volunteer . Volunteers hospitalize Johns Hopkins Phase 1 unit infusion 24-hour blood draw . Three escalate dose cohort combination three anti-botulinum monoclonal antibody evaluate . Each cohort consist eight volunteer receive single intravenous infusion active drug placebo . Placebo normal saline . Volunteers follow safety 120 day infusion depend dose cohort .</detailed_description>
	<mesh_term>Botulism</mesh_term>
	<criteria>Informed consent understood sign Healthy male healthy , nonpregnant , nonlactating female Willingness comply available protocol procedure Age 18 45 year , inclusive day infusion Body Mass Index &lt; 35 Blood pressure within acceptable limit ( systolic blood pressure &lt; /=140mmHg diastolic blood pressure &lt; /=90mmHg ) . If subject receive antihypertensive medication , blood pressure must well control change antihypertensive medication least 3 month . If subject female childbearing potential , negative serum pregnancy test screen negative urine serum pregnancy test within 24 hour prior infusion . If subject female childbearing potential , agree practice abstinence sexual intercourse men use acceptable contraception , duration study : A woman consider childbearing potential unless postmenopausal ( &gt; /= 1 year without menses ) surgically sterilize ( tubal ligation , bilateral oophorectomy , hysterectomy ) Acceptable contraception method restrict effective device ( Intrauterine Contraceptive Devices ( IUDs ) , NuvaRing® ) license hormonal product use method minimum 30 day prior vaccination , condom spermicidal agent , monogamous relationship vasectomize partner , successful Essure placement document confirmation test least 3 month procedure . All request screen laboratory value within range specify table , `` Acceptable Ranges Screening Labs Vital Sign Measurements '' ( Appendix B ) . Has adequate venous access infusion . The drug screen negative Breathalyzer test negative . History chronic medical condition include , limited , disorder liver , kidney , lung , heart nervous system , metabolic autoimmune/inflammatory condition would either interfere accurate assessment objective study increase risk profile subject : Diabetes Asthma require use medication year screen Autoimmune disorder , lupus , Wegener 's , rheumatoid arthritis Coronary artery disease History malignancy except lowgrade ( squamous basal cell ) skin cancer think cure Chronic renal hepatic pulmonary disease ( except previous asthma require treatment past year ) History severe allergic reaction type medication , bee sting , food , environmental factor hypersensitivity reaction immunoglobulin . Severe allergic reaction define follow : Anaphylaxis Urticaria Angioedema A mark baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 millisecond ) Clinically significant abnormal electrocardiogram screen judgment investigator Positive serology result Human Immunodeficiency Virus ( HIV ) , Hepatitis B Surface Antigen ( HBsAg ) , Hepatitis C Virus ( HCV ) antibody Febrile illness temperature &gt; 37.6°C within 7 day dose Pregnant breastfeeding Donated blood within 56 day enrollment Known allergic reaction study product component present formulation processing , list Investigator Brochure . Treatment another investigational drug within 30 day dose Receipt monoclonal antibody time past Receipt antibody ( e.g . TIG , VZIG , IVIG , IM gamma globulin ) blood transfusion within 6 month within 5 halflives specific product give Receipt live vaccine within previous 3 month within 5 halflives specific vaccine give Receipt kill vaccine within previous 1 month Lack ability fully understand inform consent ( e.g . speak read English ) Active drug alcohol use dependence , opinion investigator , would interfere adherence study requirement . Use H1 antihistamines betablockers within 5 day dose . Use following medication within 30 day prior study entry plan use study period : immunosuppressive ( except Nonsteroidal AntiInflammatory Drugs ( NSAIDS ) ) immune modulators oral corticosteroid ( topical steroid acceptable ) antineoplastic agent vaccine ( licensed investigational ) Previous exposure botulinum toxin , receipt antibody botulinum toxin , previous treatment equine antitoxin Any previous injection plan injection within 12 month enrollment botulinum toxin cosmetic reason , spastic dysphonia , torticollis , reason Any specific condition judgment investigator precludes participation could affect subject safety ; Coenrollment another study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Botulism , Clostridium</keyword>
</DOC>